Search

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.

… Friday, October 25, 2024 Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required. For the past five years, a team of MSK researchers has

Nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center in August 2010. He also becomes President of Gerstner Sloan Kettering Graduate School of Biomedical Sciences.

… Wednesday, December 15, 2010 In August 2010, nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center. He succeeded Harold Varmus, now Director of the National Cancer Institute. Dr. Thompson also

Cancer doesn’t stop for a pandemic, but as local governments around the nation mandated the stoppage of elective surgery, Memorial Sloan Kettering Cancer Center (MSK) surgeons had to consider several critical questions.

… Tuesday, May 12, 2020 Cancer doesn’t stop for a pandemic, but as local governments around the nation mandated the stoppage of elective surgery, Memorial Sloan Kettering Cancer Center (MSK) surgeons had to consider several critical questions: What is elective cancer surgery, and what is essential cancer

Total gastrectomy is indicated for patients with stomach cancer gene mutations regardless of family history.

… Monday, November 9, 2020 Risk-reducing prophylactic total gastrectomy may be warranted for patients with pathogenic or likely pathogenic CDH1 variants and a family history of gastric cancer or lobular breast cancer. Moreover, it should be considered for patients with CDH1 variants who do not have a family

For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.

… Sunday, September 8, 2013 For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery

Dr. Gary Deng of the Integrative Medicine Service helps separate the hype from the proven health benefits of mushroom supplements.

… Tuesday, October 22, 2024 Mushrooms have always had an aura of special power about them. People all over the world have used them as medicine in the treatment of infection, lung disease, cancer, and other conditions for thousands of years. They have long been central to traditional medicine throughout

MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. While there is a significant threat to pediatric cancer research stemming from COVID-19’s impact on philanthropy, several organizations helped MSK recognize pediatric cancer awareness month by fundraising for MSK Kids.

… Friday, October 16, 2020 MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. Our clinicians and care teams are engaged in groundbreaking research that will continue to create tomorrow’s breakthroughs. While there is a significant threat to pediatric cancer

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

… Thursday, October 28, 2021 For people with lung cancer , drug resistance is the major cause of relapse. A tumor might respond very well at first — maybe even shrinking down to an undetectable level — only to develop resistance and grow back. Scientists are learning that one of the ways that lung cancers

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.

… Friday, October 24, 2025 Immunotherapy drugs called  checkpoint inhibitors  are a promising cancer treatment, but so far only a minority of people respond to them. This has been especially notable in the treatment of  prostate cancer , the most common cancer in men, after skin cancer. Researchers at

Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.

… Tuesday, September 20, 2016 Gerstner Sloan Kettering graduate James Mahaffey works in a lab at the Perlmutter Cancer Center at NYU School of Medicine exploring the RAS gene, which is mutated in nearly a third of cancers but has resisted targeting with drugs. James Mahaffey studies RAS, a gene that is